<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30289537</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1462-0332</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>57</Volume>                    <Issue>57 Suppl 7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>10</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Rheumatology (Oxford, England)</Title>                <ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation>            </Journal>            <ArticleTitle>The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference.</ArticleTitle>            <Pagination>                <MedlinePgn>vii11-vii22</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/key209</ELocationID>            <Abstract>                <AbstractText Label="Objective">To define the safety and efficacy of TNF inhibitors (TNFi) in RA patients with comorbidities.</AbstractText>                <AbstractText Label="Methods">A National Consensus Conference adopted a five-step process to better address the place of TNFi in the treatment of RA. Here we report the work focused on the influence of comorbidities on TNFi efficacy and the effect of TNFi on comorbidities using a Population Intervention Comparison Outcome-based strategy from 8 April 2013 to 15 January 2016.</AbstractText>                <AbstractText Label="Results">A total of 4453 hits were analysed, of which 10 were eligible for full review. Data show that the presence of comorbidities influences the treatment strategy and several clinical outcomes. The risk of solid cancer is similar in RA patients treated with TNFi or with conventional synthetic DMARDs, and the risk of recurrent breast cancer is not higher in RA patients treated with TNFi. The risk of developing serious infections is higher in RA patients receiving TNFi than conventional synthetic DMARDs. Patients with previous serious infections before starting TNFi are not at increased risk of subsequent serious infection. The hazard rate of hospitalization due to infections is not different among patients remaining on the same TNFi, or switching to a different TNFi or to an agent with another mechanism of action. Longer exposure to TNFi is associated with a reduction in the risk of cardiovascular events.</AbstractText>                <AbstractText Label="Conclusion">Comorbidities affect RA treatment strategies and the efficacy of TNFi. TNFi treatment may decrease the risk of cardiovascular diseases and their use in patients with previous infection is not associated with a higher risk of recurrences.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Conti</LastName>                    <ForeName>Fabrizio</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Atzeni</LastName>                    <ForeName>Fabiola</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, University of Messina, Messina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Massaro</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chiara Gerardi</LastName>                    <ForeName>Maria</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, University of Messina, Messina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gremese</LastName>                    <ForeName>Elisa</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Rheumatology, Fondazione Policlinico Gemelli, Catholic University of the Sacred Heart, Rome.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Passiu</LastName>                    <ForeName>Giuseppe</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carletto</LastName>                    <ForeName>Antonio</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, Department of Medicine, University Hospital, Verona.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Malavolta</LastName>                    <ForeName>Nazzarena</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Gestione delle Malattie Reumatiche, Connettivo e Malattie Metaboliche dell'Osso AOU di Bologna, Policlinico S. Orsola-Malpighi, Bologna.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Foti</LastName>                    <ForeName>Rosario</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit A.O.U. Policlinico V.E. Catania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ramonda</LastName>                    <ForeName>Roberta</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rheumatology, University of Padova, Padova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarzi-Puttini</LastName>                    <ForeName>Piercarlo</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Rheumatology Unit, University of Messina, Messina.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Rheumatology (Oxford)</MedlineTA>            <NlmUniqueID>100883501</NlmUniqueID>            <ISSNLinking>1462-0324</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003245" MajorTopicYN="N">Consensus Development Conferences as Topic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007239" MajorTopicYN="N">Infection</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>08</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30289537</ArticleId>            <ArticleId IdType="pii">5115899</ArticleId>            <ArticleId IdType="doi">10.1093/rheumatology/key209</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>